

---

**CORRIGENDUM**

## Vaccines for the twenty-first century society

*Rino Rappuoli, Christian W. Mandl, Steven Black and Ennio De Gregorio*

*Nature Reviews Immunology* **11**, 865–872 (2011)

On page 872 of the original version of this article, under the subheading “New vaccine development technologies”, there was an error in the sentence that began: “AS04 (GlaxoSmithKline), an adjuvant composed of aluminium salt and the Toll-like receptor (TLR) agonist MPL”. This sentence should begin: “AS04 (GlaxoSmithKline), an adjuvant composed of aluminium salt and the Toll-like receptor (TLR) agonist MPL”. The authors apologize for this error.